Analyzing the Survival Benefits of Niraparib Dose Modification in Ovarian Cancer

March 19, 2019
Ursula A. Matulonis, MD

Ursula A. Matulonis, MD, discusses the survival results from an analysis of the QUADRA trial in heavily pretreated patients with recurrent ovarian cancer.

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the survival results froman analysis of the QUADRA trialin heavily pretreated patients with recurrent ovarian cancer.

Patients with a platelet count greater than 150 and a body weight over 77 kg received a starting dose of niraparib (Zejula) at 200 mg. In this group, overall survival (OS) was a little less than those who were started at 300 mg, Matulonis says.